Proportional differences in demographic representation in pivotal clinical trials for lymphoma therapies approved between 2011 and 2021 and the 2018 SEER incidence data
| . | RCTs . | SEER . | ꭕ2 . | P value . |
|---|---|---|---|---|
| % (95% CI) . | % (95% CI) . | |||
| cHL | (n = 1957) | (n = 8179) | ||
| Black | 3.6 (2.8-4.5) | 14.6 (13.8-15.3) | 173.2 | < .0001 |
| White | 85.8 (84.3-87.3) | 81.5 (80.7-82.3) | 19.7 | < .0001 |
| Asian-PI | 6.6 (5.5-7.7) | 3.9 (3.5-4.3) | 28 | < .0001 |
| Native American | 0.1 (0-2.4) | NR 0 (0-0) | 8.4 | .0038 |
| ∗Hispanic | 6.7 (5.5-7.9) | 16.3 (15.5-17.1) | 98.9 | < .0001 |
| Female | 42.7 (40.5-44.9) | 44.7 (43.6-45.8) | 2.6 | .104 |
| Male | 57.3 (55.1-60) | 57.1 (56-58.2) | 0.04 | .8348 |
| NHL | (n = 2892) | (n = 63 470) | ||
| Black | 2.8 (2.2-3.4) | 10.7 (10.4-10.9) | 185.3 | < .0001 |
| White | 81.4 (79.9-82.8) | 79.8 (79.5-80.1) | 4.3 | .0381 |
| Asian-PI | 6.1 (5.2-6.9) | 5.1 (4.8-5.2) | 5.7 | .0168 |
| Native American | 0.3 (0.1-0.5) | 0.1 (0.96-0.11) | 14.8 | .0001 |
| ∗Hispanic | 5.4 (4.4-6.4) | 17.1 (16.8-17.4) | 188.9 | < .0001 |
| Female | 39.1 (37.3-40.9) | 42.7 (42.3-43.1) | 14.7 | .0001 |
| Male | 60.9 (59.2-62.3) | 59.1 (58.7-59.5) | 3.9 | .0495 |
| . | RCTs . | SEER . | ꭕ2 . | P value . |
|---|---|---|---|---|
| % (95% CI) . | % (95% CI) . | |||
| cHL | (n = 1957) | (n = 8179) | ||
| Black | 3.6 (2.8-4.5) | 14.6 (13.8-15.3) | 173.2 | < .0001 |
| White | 85.8 (84.3-87.3) | 81.5 (80.7-82.3) | 19.7 | < .0001 |
| Asian-PI | 6.6 (5.5-7.7) | 3.9 (3.5-4.3) | 28 | < .0001 |
| Native American | 0.1 (0-2.4) | NR 0 (0-0) | 8.4 | .0038 |
| ∗Hispanic | 6.7 (5.5-7.9) | 16.3 (15.5-17.1) | 98.9 | < .0001 |
| Female | 42.7 (40.5-44.9) | 44.7 (43.6-45.8) | 2.6 | .104 |
| Male | 57.3 (55.1-60) | 57.1 (56-58.2) | 0.04 | .8348 |
| NHL | (n = 2892) | (n = 63 470) | ||
| Black | 2.8 (2.2-3.4) | 10.7 (10.4-10.9) | 185.3 | < .0001 |
| White | 81.4 (79.9-82.8) | 79.8 (79.5-80.1) | 4.3 | .0381 |
| Asian-PI | 6.1 (5.2-6.9) | 5.1 (4.8-5.2) | 5.7 | .0168 |
| Native American | 0.3 (0.1-0.5) | 0.1 (0.96-0.11) | 14.8 | .0001 |
| ∗Hispanic | 5.4 (4.4-6.4) | 17.1 (16.8-17.4) | 188.9 | < .0001 |
| Female | 39.1 (37.3-40.9) | 42.7 (42.3-43.1) | 14.7 | .0001 |
| Male | 60.9 (59.2-62.3) | 59.1 (58.7-59.5) | 3.9 | .0495 |
NR, not reported: SEER does not report data if total cases are <16.
Proportions of Hispanic persons in the RCTs were calculated using total participants from trials that reported data on ethnicity.